Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A marked decrease of vasoactive intestinal peptide release in obese patients.

B Baranowska1

  • 1Neuroendocrinology Department, Medical Center of Postgraduate Education, Warsaw, Poland.

Metabolism: Clinical and Experimental
|April 1, 1991
PubMed
Summary

Obese patients exhibit significantly lower vasoactive intestinal peptide (VIP) levels, potentially impacting growth hormone (GH) release. Clonidine did not affect VIP or prolactin (PRL) but showed a blunted GH response in obese individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of CART on pituitary hormones release from cultured pituitary cells harvested from fasted and fed ad libitum male rats.

Peptides·2017
Same author

Total and high molecular weight adiponectin levels in the rat model of post-myocardial infarction heart failure.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2015
Same author

Effect of orexin A on the release of GnRH-stimulated gonadotrophins from cultured pituitary cells of immature and mature female rats.

Neuropeptides·2014
Same author

Leptin and ghrelin concentrations and weight loss in Parkinson's disease.

Acta neurologica Scandinavica·2009
Same author

Cortistatin and pituitary hormone secretion in rat.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2009
Same author

Neuroendocrine control of metabolic homeostasis in Polish centenarians.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2007

Area of Science:

  • Neuroendocrinology
  • Hormone Regulation
  • Obesity Research

Background:

  • Vasoactive intestinal peptide (VIP) is present in key neuroendocrine areas, suggesting a role in pituitary hormone regulation.
  • The adrenergic system influences prolactin (PRL) and growth hormone (GH) release, but its interaction with VIP in obesity is unclear.

Purpose of the Study:

  • To investigate the relationship between VIP and the adrenergic system in the context of obesity.
  • To determine the role of VIP in disturbed PRL and GH release mechanisms in obese patients.

Main Methods:

  • Measurement of serum VIP, GH, and PRL concentrations.
  • Administration of clonidine, an alpha 2-adrenergic receptor agonist, to assess hormonal responses.
  • Comparison of hormonal levels and responses between obese and non-obese individuals.

Related Experiment Videos

Main Results:

  • Serum VIP levels were markedly lower in obese patients compared to non-obese controls.
  • Clonidine administration did not alter VIP or PRL concentrations in either group.
  • The GH response to clonidine injection was blunted in obese patients.

Conclusions:

  • Obesity is associated with an inhibited release of VIP.
  • The potential role of decreased VIP in the disturbed release of GH and PRL in obesity requires further investigation.